Suppr超能文献

鼻窦鼻腔鳞状细胞癌眶侵犯的处理:15 年经验。

Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years' experience.

机构信息

Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.

出版信息

Int Forum Allergy Rhinol. 2020 Feb;10(2):243-255. doi: 10.1002/alr.22465. Epub 2019 Nov 22.

Abstract

BACKGROUND

This study was intended to review our management strategy for sinonasal squamous cell carcinomas (SNSCCs) with orbital invasion and to explore the role of radiotherapy in orbital preservation.

METHODS

We retrospectively analyzed 93 SNSCC patients with orbital invasion who underwent radiotherapy with or without surgery over the past 15 years. The degree of orbital invasion was classified into 3 grades.

RESULTS

Eighty-eight patients presented with T4 tumors and 36 had grade III orbital invasion. Seventy-two patients received surgery plus radiation and 67 received platinum-based chemotherapy. The median follow-up for surviving patients was 60 months. Five-year overall survival (OS) for the whole group was 57.4%. The patients treated with surgery plus radiation had a 5-year survival rate of 62.2% and orbital preservation was feasible in 90.3% of cases. Twenty-one patients with SNSCCs that extended into the extraocular muscles or eye globe also underwent orbital preservation. Five-year locoregional relapse-free survival (LRFS) was 69.5% for patients treated with orbital preservation and 57.1% for those treated with orbital exenteration, indicating no statistical difference. Five-year survival, 5-year progression-free survival (PFS), and 5-year distant metastasis-free survival (DMFS) were similar between groups. Grade III orbital invasion was independently associated with shorter OS, LRFS, PFS, and DMFS.

CONCLUSION

Orbital invasion in grade III was associated with the worst survival outcomes. Invasion of either the extraocular muscles or eye globe is not a contraindication for eye-sparing surgery. Preoperative chemoradiation continues to offer hope to patients with a strong desire to preserve their eyes.

摘要

背景

本研究旨在回顾我们对合并眼眶侵犯的鼻腔鼻窦鳞状细胞癌(SNSCC)的治疗策略,并探讨放疗在保留眼眶中的作用。

方法

我们回顾性分析了过去 15 年中 93 例接受放疗联合或不联合手术治疗的合并眼眶侵犯的 SNSCC 患者。眼眶侵犯程度分为 3 级。

结果

88 例患者表现为 T4 肿瘤,36 例患者为 III 级眼眶侵犯。72 例患者接受手术联合放疗,67 例患者接受铂类为基础的化疗。生存患者的中位随访时间为 60 个月。全组患者 5 年总生存率(OS)为 57.4%。接受手术联合放疗的患者 5 年生存率为 62.2%,90.3%的病例可行眼眶保留。21 例累及眼外肌或眼球的 SNSCC 患者也进行了眼眶保留。接受眼眶保留治疗的患者 5 年局部区域无复发生存率(LRFS)为 69.5%,接受眼眶剜除术治疗的患者为 57.1%,差异无统计学意义。两组患者 5 年生存率、5 年无进展生存率(PFS)和 5 年无远处转移生存率(DMFS)相似。III 级眼眶侵犯与 OS、LRFS、PFS 和 DMFS 较短有关。

结论

III 级眼眶侵犯与最差的生存结果相关。眼外肌或眼球受累不是保眼手术的禁忌证。术前放化疗仍然为有强烈保眼愿望的患者带来希望。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验